# Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma.

> **NCT05919381** · PHASE3 · UNKNOWN · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 752 (estimated)

## Conditions studied

- Adenocarcinoma of Stomach

## Interventions

- **DRUG:** Gentuximab Injection
- **DRUG:** Gentuximab Injection Placebo

## Key facts

- **NCT ID:** NCT05919381
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-30
- **Primary completion:** 2024-12
- **Final completion:** 2025-01
- **Target enrollment:** 752 (ESTIMATED)
- **Last updated:** 2023-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05919381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05919381, "Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05919381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*